Aspira Women's Health Inc. (AWHL): Nasdaq/NYSE listing notice — Aspira Women's Health receives Nasdaq delisting notice for MVLS below $35M

Aspira Women's Health Inc.

Nasdaq notified Aspira on July 11, 2023 that its Market Value of Listed Securities was below $35M for 30 consecutive business days.
Company has 180-day grace period, until January 8, 2024, to regain compliance with the MVLS requirement.
To regain compliance, MVLS must be $35M+ for 10 consecutive business days; alternative is equity above $2.5M.
If not compliant by deadline, Nasdaq may delist stock; Aspira may appeal any delisting determination.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2), 5810(c)(3)(C)

Exact text from the filing

July 11, 2023, Aspira Women’s Health Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the Company’s minimum Market Value of Listed Securities was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Compan

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-23-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.